Inventor · disambiguated record
Thierry Leveillard
Also filed as: LEVEILLARD THIERRY
16 granted patents·15 pending applications·91 citations·filing 2002–2024
93Inventor score
Files withINST NAT SANTE RECH MED14LEVEILLARD THIERRY7NOVARTIS AG2PERROCHEAU LUDIVINE2SPARINGVISION2
Top patents by PatentIndex Score
31 records- 0193US8518695B2Compositions comprising polynucleotides encoding RDCVF1 or RDCVF2LEVEILLARD THIERRY·Filed 2012·Granted Aug 27, 2013·13 cites·16 claims
- 0293US8394756B2Methods of increasing RDCVF 1 or RDCVF 2 polypeptides in retinal cellsLEVEILLARD THIERRY·Filed 2012·Granted Mar 12, 2013·14 cites·10 claims
- 0393US8114849B2Retinal dystrophy-associated protein and uses thereofLEVEILLARD THIERRY·Filed 2007·Granted Feb 14, 2012·15 cites·6 claims
- 0490US8071745B2Polynucleotides encoding rod-derived cone viability factor (rdcvf) and methods of using the sameLEVEILLARD THIERRY·Filed 2007·Granted Dec 6, 2011·14 cites·8 claims
- 0588US8957043B2Methods of treating retinitis pigmentosa using nucleic acids encoding RDCVF1 or RDCVF2NOVARTIS AG·Filed 2013·Granted Feb 17, 2015·4 cites·15 claims
- 0684US7795387B2Rod-derived cone viability factor (RDCVF) and a method of enhancing cone cell survival by RDCVFNOVARTIS AG·Filed 2002·Granted Sep 14, 2010·13 cites·7 claims
- 0782US9575075B2Methods for treating cone dystrophy with neuronal viability factor, RDCVF2LEVEILLARD THIERRY·Filed 2008·Granted Feb 21, 2017·2 cites·1 claims
- 0880US8779093B2Neuronal viability factor and use thereofLEVEILLARD THIERRY·Filed 2009·Granted Jul 15, 2014·5 cites·5 claims
- 0980US8193153B2Trophic factor for the treatment of retinal degenerative diseasesLEVEILLARD THIERRY·Filed 2008·Granted Jun 5, 2012·5 cites·7 claims
- 1079US2025059563A1Constructs comprising neuronal viability factors and uses thereofSPARINGVISION·Filed 2024·Application pending·0 cites
- 1178US10668129B2Synergistic combination of neuronal viability factors and uses thereofINST NAT SANTE RECH MED·Filed 2016·Granted Jun 2, 2020·2 cites·5 claims
- 1277US10004780B2Methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD)INST NAT SANTE RECH MED·Filed 2013·Granted Jun 26, 2018·2 cites·6 claims
- 1376US11428698B2Neuronal viability factor and use thereof in Alzheimer's diseaseINST NAT SANTE RECH MED·Filed 2019·Granted Aug 30, 2022·1 cites·2 claims
- 1475US2022404376A1Neuronal viability factor and use thereofINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 1573US11723988B2Methods of expressing a polynucleotide of interest in the cone photoreceptors of a subject comprising the subretinal delivery of a therapeutically effective amount of a recombinant AAV9-derived vectorINST NAT SANTE RECH MED·Filed 2018·Granted Aug 15, 2023·1 cites·7 claims
- 1669US2019064189A1Neuronal viability factor and use thereofINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 1763US2025084069A1Geralexin and uses thereof for the treatment of retinal degenerative diseasesINST NAT SANTE RECH MED·Filed 2023·Application pending·0 cites
- 1860US2017014478A1Neuronal viability factor and use thereofINST NAT DE LA SANTE ET DE LAS RECH MEDICALE·Filed 2016·Application pending·0 cites
- 1959US2015038557A1Methods and compositions for treatment of retinal degenerative diseasesINST NAT SANTE RECH MED·Filed 2013·Application pending·0 cites
- 2058US2020318138A1Constructs comprising neuronal viability factors and uses thereofSPARINGVISION·Filed 2018·Application pending·0 cites
- 2156US10857239B2Methods for the treatment and diagnosis of Alzheimer's disease and traumatic brain injuriesINST NAT SANTE RECH MED·Filed 2016·Granted Dec 8, 2020·0 cites·8 claims
- 2256US2021069346A1Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain InjuriesINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
- 2355US2021308169A1Methods and compositions for treatment of retinal degenerative diseasesINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 2455US2025276088A1Synergistic combination of rdcfv2 and rdcvf2l for the treatment of tauopathiesINST NAT SANTE RECH MED·Filed 2022·Application pending·0 cites
- 2554US2016213701A1Methods and compositions for treatment of retinal degenerative diseasesINSERM (INSTITUT NAT DE LA SANTE ET DE LA RECH MEDICALE)·Filed 2016·Application pending·0 cites
- 2648US2021338773A1Method for treating retinal degeneration disease by administering nucleolin polynucleotide or polypeptideINST NAT SANTE RECH MED·Filed 2018·Application pending·0 cites
- 2745US11313852B2Method and pharmaceutical composition for use in the treatment of neurodegenerative disordersPERROCHEAU LUDIVINE·Filed 2017·Granted Apr 26, 2022·0 cites·2 claims
- 2845US2019328846A1Pharmaceutical compositions for the treatment of retinal degenerative diseasesINST NAT SANTE RECH MED·Filed 2017·Application pending·0 cites
- 2942US2023033235A1Nptn65 is a new target for the treatment of tauopathiesINSERM INSTITUT NATIONAL DE LAS SANTE ET DE LA RECH MEDICALE·Filed 2021·Application pending·0 cites
- 3041US11865189B2Transgenic RPE cells overexpressing OTX2 for the treatment of retinal degenerationUNIV SORBONNE·Filed 2015·Granted Jan 9, 2024·0 cites·18 claims
- 3135US2012156221A1Method and Pharmaceutical Composition for Use in the Treatment of Neurodegenerative DisordersPERROCHEAU LUDIVINE·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Thierry Leveillard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →